Tumor-associated glycoprotein 72

Last updated

Tumor-associated glycoprotein 72 (TAG-72) is a glycoprotein that appears on the surface of many cancer cells, including those from the ovary, [1] [2] [3] breast, colon, [4] lung, and pancreatic cancers. [5] [6] TAG-72 is a mucin-like molecule with a molar mass of over 1000 kDa, and is classified as a tumor-associated glycoprotein. [7]

Contents

Discovery

Researchers identified Tumor-associated glycoprotein 72 (TAG-72) in the mid-1980s during the development of the Monoclonal antibody B72.3. These antibodies selectively bound to a high-molecular-weight glycoprotein found on various Carcinoma cells. Later studies confirmed TAG-72 as a Mucin-like molecule with significant Glycosylation, which adds to its high molecular weight. [8] This discovery has supported advancements in cancer diagnostics and therapeutics, especially those targeting TAG-72-expressing tumors. [9]

Structure

TAG-72.png

TAG-72 is a high-molecular-weight glycoprotein(>1,000 Kda), primarily expressed on the surface of various Adenocarcinomas. Its structure is features extensive O-linked glycosylation, [9] which gives it a mucin-like configuration. [9] [10] [8] The glycosylation patterns of TAG-72 include tumor-associated carbohydrate antigens such assialyl-Tn (STn) and Thomsen–Friedenreich antigens, which are contribute to tumor progression and metastasis. [11] These carbohydrate epitopes serve as binding sites for monoclonal antibodies like B72.3 and CC49, enabling targeted cancer detection and treatment. [9]

Pathogenic mechanism

TAG-72 rarely appears in normal adult tissues but is highly present in malignant epithelial cells, which makes it a Tumor-specific antigen. [8] It plays a role in:

Clinical applications

1. Tumor Marker (CA 72-4 Assay)

There was a significant difference (p = 0.005) in the proportion surviving between those patients with no residual TAG-72-positive tissue at the end of surgery (red dashed line) as compared to those patients where residual TAG-72-positive tissue (blue dashed line) remained at the end of surgery. Patient prognosis based on TAG-72 presence after cancer removal surgery.jpg
There was a significant difference (p = 0.005) in the proportion surviving between those patients with no residual TAG-72-positive tissue at the end of surgery (red dashed line) as compared to those patients where residual TAG-72-positive tissue (blue dashed line) remained at the end of surgery.

TAG-72 is commonly measured with radioimmunoassays like CA 72-4, [14] which uses the monoclonal antibodies indium (111In) satumomab pendetide and iodine (125I) minretumomab. [15] [16] [17] [18] [19] This assay has a good specificity for gastric cancer, with a correlation to the neoplasia's extension. It is used for:

Since TAG-72 is tumor-specific, it is a promising target for immunotherapy and antibody-drug conjugates:

Cancer association

TAG-72 is mainly found in epithelial-derived malignancies, including:

Gastrointestinal

Gynecological

Other cancers

References

  1. ↑ Ponnusamy MP, Venkatraman G, Singh AP, Chauhan SC, Johansson SL, Jain M, et al. (2007-06-28). "Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis". Cancer Letters. 251 (2): 247–257. doi:10.1016/j.canlet.2006.11.025. PMID   17210225.
  2. ↑ Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, et al. (2018-11-19). "Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells". Frontiers in Immunology. 9: 2268. doi: 10.3389/fimmu.2018.02268 . PMC   6254427 . PMID   30510550.
  3. ↑ Shu R, Evtimov VJ, Hammett MV, Nguyen NN, Zhuang J, Hudson PJ, et al. (2021-01-16). "Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer". Molecular Therapy Oncolytics. 20: 325–341. doi:10.1016/j.omto.2021.01.002. PMC   7868933 . PMID   33614914.
  4. ↑ Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. (2017-03-21). "Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer". Journal for Immunotherapy of Cancer. 5 22. doi: 10.1186/s40425-017-0222-9 . PMC   5360066 . PMID   28344808.
  5. ↑ TAG-72 antigen entry in the public domain NCI Dictionary of Cancer Terms
  6. ↑ Scott AM, Wolchok JD, Old LJ (Mar 2012). "Antibody therapy of cancer". Nature Reviews. Cancer. 12 (4): 278–287. doi:10.1038/nrc3236. PMID   22437872. S2CID   205469234.
  7. ↑ Sheer DG, Schlom J, Cooper HL (Dec 1988). "Purification and Composition of the Human Tumor-associated Glycoprotein (TAG-72) Defined by Monoclonal Antibodies CC49 and B72.3". Cancer Research. 48 (23): 6811–6818. PMID   3180090.
  8. 1 2 3 Chopra A (2004), "99mTc-Labeled tumor-associated glycoprotein 72 binding peptides A2-6 and A3-10", Molecular Imaging and Contrast Agent Database (MICAD), Bethesda (MD): National Center for Biotechnology Information (US), PMID   22049573 , retrieved 2025-04-19
  9. 1 2 3 4 5 6 Hitchcock CL, Povoski SP, Mojzisik CM, Martin EJ (2021-12-07). "Survival Advantage Following TAG-72 Antigen-Directed Cancer Surgery in Patients With Colorectal Carcinoma: Proposed Mechanisms of Action". Frontiers in Oncology. 11: 731350. doi: 10.3389/fonc.2021.731350 . ISSN   2234-943X. PMC   8688248 . PMID   34950576.
  10. ↑ Riley NM, Wen RM, Bertozzi CR, Brooks JD, Pitteri SJ (2023). "Measuring the multifaceted roles of mucin-domain glycoproteins in cancer". Advances in Cancer Research. 157: 83–121. doi:10.1016/bs.acr.2022.09.001. ISBN   978-0-323-99177-3. ISSN   2162-5557. PMC   10582998 . PMID   36725114.
  11. ↑ Rajesh C, Radhakrishnan P (2023-01-06). "The (Sialyl) Tn antigen: Contributions to immunosuppression in gastrointestinal cancers". Frontiers in Oncology. 12: 1093496. doi: 10.3389/fonc.2022.1093496 . ISSN   2234-943X. PMC   9852904 . PMID   36686742.
  12. ↑ Bhatia R, Gautam SK, Cannon A, Thompson C, Hall BR, Aithal A, et al. (June 2019). "Cancer-associated mucins: role in immune modulation and metastasis". Cancer and Metastasis Reviews. 38 (1–2): 223–236. doi:10.1007/s10555-018-09775-0. ISSN   1573-7233. PMC   6614013 . PMID   30618016.
  13. ↑ Laubli H, Borsig L (2019). "Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis". Frontiers in Immunology. 10: 2120. doi: 10.3389/fimmu.2019.02120 . ISSN   1664-3224. PMC   6743365 . PMID   31552050.
  14. ↑ Guadagni F, Roselli M, Amato T, Cosimelli M, Perri P, Casale V, et al. (1992-03-01). "CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma". Cancer Research. 52 (5): 1222–1227. ISSN   0008-5472. PMID   1737383.
  15. ↑ Louhimo J, Alfthan H, Stenman UH, Haglund C (2004). "Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer" . Oncology. 66 (2): 126–131. doi:10.1159/000077438. PMID   15138364. S2CID   25798287.
  16. ↑ Louhimo J, Carpelan-Holmström M, Alfthan H, Stenman UH, Järvinen HJ, Haglund C (October 2002). "Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer". International Journal of Cancer. 101 (6): 545–548. doi: 10.1002/ijc.90009 . PMID   12237895.
  17. ↑ Louhimo J, Kokkola A, Alfthan H, Stenman UH, Haglund C (October 2004). "Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer". International Journal of Cancer. 111 (6): 929–933. doi: 10.1002/ijc.20321 . PMID   15300805. S2CID   24698852.
  18. ↑ Mattar R, Alves de Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA (2002). "Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer". Revista do Hospital das Clinicas. 57 (3): 89–92. doi: 10.1590/s0041-87812002000300001 . PMID   12118264.
  19. ↑ Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, et al. (November 1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Research. 56 (22): 5293–5298. PMID   8912871.
  20. ↑ Guadagni F, Roselli M, Ferroni P, Amato T, Colcher D, Greiner JW, et al. (1991). "Clinical evaluation of the new tumor marker TAG-72". Anticancer Research. 11 (4): 1389–1394. ISSN   0250-7005. PMID   1746895.
  21. ↑ "Anti-TAG-72 [Minretumomab (CC49 )]". Absolute Antibody. Retrieved 2025-04-19.
  22. ↑ "Anti-Human TAG-72 Recombinant Antibody(Anatumomab Mafenatox) - KMD Bioscience-Nanobody Discovery Platform, Protein Expression Systems, and CRO Service Supplier". www.kmdbioscience.com. Retrieved 2025-04-19.
  23. ↑ Shu R, Evtimov VJ, Hammett MV, Nguyen NN, Zhuang J, Hudson PJ, et al. (2021-03-26). "Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer". Molecular Therapy Oncolytics. 20: 325–341. doi:10.1016/j.omto.2021.01.002. ISSN   2372-7705. PMC   7868933 . PMID   33614914.
  24. ↑ Cho J, Kim KM, Kim HC, Lee WY, Kang WK, Park YS, et al. (January 2019). "The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma". Pathology, Research and Practice. 215 (1): 171–176. doi:10.1016/j.prp.2018.10.024. ISSN   1618-0631. PMID   30466765.
  25. ↑ Xu Y, Zhang P, Zhang K, Huang C (2021-12-01). "The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1876 (2) 188634. BBA. doi: 10.1016/j.bbcan.2021.188634 . ISSN   0304-419X. PMID   34656687.
  26. ↑ Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S (June 1994). "Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9". International Journal of Pancreatology. 15 (3): 171–177. doi:10.1007/BF02924191. ISSN   0169-4197. PMID   7930777.
  27. ↑ Ponnusamy MP, Venkatraman G, Singh AP, Chauhan SC, Johansson SL, Jain M, et al. (2007-06-28). "Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis". Cancer Letters. 251 (2): 247–257. doi:10.1016/j.canlet.2006.11.025. ISSN   0304-3835. PMID   17210225.
  28. ↑ Chen L, Wang Y, Liu X, Dou S, Liu G, Hnatowich DJ, et al. (2008-12-08). "A new TAG-72 cancer marker peptide identified by phage display". Cancer Letters. 272 (1): 122–132. doi:10.1016/j.canlet.2008.07.009. ISSN   1872-7980. PMC   2680929 . PMID   18723274.
  29. ↑ Galietta A, Pizzi C, Pettinato G, Limite G, Sgambato A, Lamberti M, et al. (2002). "Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype". Oncology Reports. 9 (1): 135–140. ISSN   1021-335X. PMID   11748471.

PD-icon.svg This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.